SI2976360T1 - Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka - Google Patents
Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje rakaInfo
- Publication number
- SI2976360T1 SI2976360T1 SI201431443T SI201431443T SI2976360T1 SI 2976360 T1 SI2976360 T1 SI 2976360T1 SI 201431443 T SI201431443 T SI 201431443T SI 201431443 T SI201431443 T SI 201431443T SI 2976360 T1 SI2976360 T1 SI 2976360T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cancer
- treatment
- antibodies against
- therapy involving
- involving antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/000817 WO2014146672A1 (en) | 2013-03-18 | 2013-03-18 | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
EP14714586.6A EP2976360B1 (en) | 2013-03-18 | 2014-03-17 | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
PCT/EP2014/000719 WO2014146778A1 (en) | 2013-03-18 | 2014-03-17 | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2976360T1 true SI2976360T1 (sl) | 2020-04-30 |
Family
ID=54867420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431443T SI2976360T1 (sl) | 2013-03-18 | 2014-03-17 | Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP3670537A1 (sl) |
HR (1) | HRP20200019T1 (sl) |
PL (1) | PL2976360T3 (sl) |
SI (1) | SI2976360T1 (sl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11555070B2 (en) * | 2018-03-08 | 2023-01-17 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
CN116333141A (zh) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
-
2014
- 2014-03-17 EP EP19210913.0A patent/EP3670537A1/en active Pending
- 2014-03-17 EP EP14714586.6A patent/EP2976360B1/en active Active
- 2014-03-17 SI SI201431443T patent/SI2976360T1/sl unknown
- 2014-03-17 PL PL14714586T patent/PL2976360T3/pl unknown
-
2020
- 2020-01-08 HR HRP20200019TT patent/HRP20200019T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20200019T1 (hr) | 2020-04-03 |
PL2976360T3 (pl) | 2020-05-18 |
EP3670537A1 (en) | 2020-06-24 |
EP2976360B1 (en) | 2019-11-27 |
EP2976360A1 (en) | 2016-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
HK1219486A1 (zh) | 用於治療癌症的涉及抗密蛋白 的抗體的療法 | |
HK1213925A1 (zh) | 用於治療癌症的涉及抗密蛋白 抗體的組合療法 | |
RS56187B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
SI2976360T1 (sl) | Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka | |
RS63738B1 (sr) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera |